https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-10 09:26:452025-09-12 09:40:44Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-10 09:26:452025-09-12 09:40:44Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants
Study demonstrated the use of immortalized B-cell libraries…

Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented at EBJIS 2025
Randomised, double-blinded, controlled BIG D-FOOT study demonstrates…

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025
DO-2 is a best-in-class MET kinase inhibitor that has completed…

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support
CTH120 is a first-in-class neuroplasticity modulator with…

Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman
Dr. Blackman is an Entrepreneur-in-Residence at Google Ventures…

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth
Funding enables AMSilk to scale industrial production and…

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
Follows successful completion of pre-clinical activities by Alchemab…

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes (France), September 8, 2025 – Servier, an independent…

Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors
Seasoned executive with three decades of experience in pharma…

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
RTX001 is the first engineered Regenerative Macrophage Therapy…

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump
Led by new investor Innovation Industries, with matching contributions…

Novo Holdings co-leads Phasecraft’s $34 million Series B financing to bring quantum computing closer to solving real-world challenges
New funding follows US expansion and will accelerate Phasecraft’s…

Advanced Medical Solutions Group plc – Notice of Interim Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS),…

Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
London, UK – 28 August 2025 – Leucid Bio ("Leucid" or the…

Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper
Resolution leadership team joined by world leading clinical…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York